Science|Business
Policy Analysis: Investment, Life Sciences, Policy
Published: 28 June 2012
Support innovation by using innovation – and pay a fair price

Andrew Witty

The pharmaceutical industry – Europe’s most R&D intensive sector – is being damaged by cuts to drugs budgets. This will drive investment in innovation elsewhere, the EU is warned in a letter from Andrew Witty, president of EFPIA


Andrew Witty, CEO of GlaxoSmithKline and President of the European Federation of Pharmaceutical Industries and Associations

Innovation is vital to any successful long-term economic strategy. I am writing to ask that during the European Council in Brussels on 28-29 June, EU leaders show support for pharmaceutical innovation as one of the key platforms of a growth programme for Europe.

Europe is already a world leader in the pharmaceutical sector, built on decades of investment and on the great foundations of European universities and intellectual leadership. However, other locations such as the US and...

This page requires a Science|Business Network Membership

This page is available to Science|Business Network Members only. If you are already a member then please log in (above).

Note if you are only registered to receive our Bulletin, or have previously purchased an item from our store, this does not give you access to the full benefits of the site. Join Now and plug into the Science|Business Network to get full access to all our news, events and business opportunities.

Science|Business is the first independent media company that brings together researchers, investors and policy makers in the European innovation community. It does so with a top-quality team and unique network of Europe's leading scientific institutions, corporations, policy makers and IP and VC specialists.

Be where innovation begins – become a member. Click here to learn more.



Related subjects:

Advertisement